🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "huge turning point" in the fight against drug-resistant strains of the infection, according to researchers.

A Global Public Health Issue

Cases of gonorrhoea are on the rise globally, with data suggesting over 82 million new cases annually. Especially elevated rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary step in the face of increasing worldwide cases, escalating drug resistance and the highly restricted available drugs at this time.”

Medical experts are particularly alarmed about the increase in treatment-resistant strains. The World Health Organization has classified it as a "priority pathogen". Recent surveillance revealed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Drugs Receive Approval

Zoliflodacin, also known as a brand name, was approved by the American regulatory agency in mid-December for use against gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Scientists anticipate that focused deployment of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, also received approval in the same week. This treatment, which is employed against UTIs, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Partnership

This new treatment stemmed from a new, not-for-profit approach for drug creation. The non-profit organisation GARDP collaborated with the drug firm its industry partner to see it through.

“This authorization represents a major breakthrough in the management of highly resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Testing Data and Global Access

Based on findings published in a major medical journal, zoliflodacin cured over nine in ten of genital gonorrhoea infections. This establishes an comparable level with the current standard treatment, which involves two antibiotics. The research enrolled nearly 1,000 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the ability to make available and distribute the drug in numerous developing nations.

Doctors treating patients have shared optimism. Access to a single-dose, oral treatment of this kind is seen as a "game-changer" for managing the epidemic. This is deemed vital to reduce the burden of the illness for patients and to prevent the spread of untreatable gonorrhoea globally.